Abstract
BackgroundEndogenous nitric oxide (NO) may contribute to ischemic and anesthetic preconditioning while exogenous NO protects against ischemia-reperfusion (I/R) injury in the heart and other organs. Why those beneficial effects observed in animal models do not always translate into clinical effectiveness remains unclear. To mitigate reperfusion damage a source of NO is required. NO inhalation is known to increase tissue NO metabolites, but little information exists about the lifetime of these species. We therefore sought to investigate the fate of major NO metabolite classes following NO inhalation in mice in vivo. MethodsC57BL/6J mice were exposed to 80 ppm NO for 1 h. NO metabolites were measured in blood (plasma and erythrocytes) and tissues (heart, liver, lung, kidney and brain) immediately after NO exposure and up to 48 h thereafter. Concentrations of S-nitrosothiols, N-nitrosamines and NO-heme products as well as nitrite and nitrate were quantified by gas-phase chemiluminescence and ion chromatography. In separate experiments, mice breathed 80 ppm NO for 1 h prior to cardiac I/R injury (induced by coronary arterial ligation for 1 h, followed by recovery). After sacrifice, the size of the myocardial infarction (MI) and the area at risk (AAR) were measured. ResultsAfter NO inhalation, elevated nitroso/nitrosyl levels returned to baseline over the next 24 h, with distinct multi-phasic decay profiles in each compartment. S/N-nitroso compounds and NO-hemoglobin in blood decreased exponentially, but remained above baseline for up to 30min, whereas nitrate was elevated for up to 3hrs after discontinuing NO breathing. Hepatic S/N-nitroso species concentrations remained steady for 30min before dropping exponentially. Nitrate only rose in blood, liver and kidney; nitrite tended to be lower in all organs immediately after NO inhalation but fluctuated considerably in concentration thereafter. NO inhalation before myocardial ischemia decreased the ratio of MI/AAR by 30% vs controls (p = 0.002); only cardiac S-nitrosothiols and NO-hemes were elevated at time of reperfusion onset. ConclusionsMetabolites in blood do not reflect NO metabolite status of any organ. Although NO is rapidly inactivated by hemoglobin-mediated oxidation in the circulation, long-lived tissue metabolites may account for the myocardial preconditioning effects of inhaled NO. NO inhalation may afford similar protection in other organs.
Highlights
Coronary artery disease (CAD; known as ‘ischemic heart disease’) is the most common type of cardiovascular disease, and most deaths from CAD are caused by a heart attack [1]
We previously reported that breathing nitric oxide (NO) reduces cardiac ischemiareperfusion (I/R) injury in animal models [18,19,20,21], that increased levels of NO metabolites in blood and tissues correlate with the cardioprotective effects of Inhaled nitric oxide (iNO) [20], and that these effects are dependent on the presence of soluble guanylate cyclase [21]
Since all samples of our earlier murine study on the metabolic fate of iNO [20] had been analyzed within minutes of specimen harvest there was a need to establish whether or not frozen blood/tissue samples could be used to study NO metabolite decay. While this is firmly established for nitrite/nitrate analysis little information is available for more labile NO adducts such as NO-heme species
Summary
Coronary artery disease (CAD; known as ‘ischemic heart disease’) is the most common type of cardiovascular disease, and most deaths from CAD are caused by a heart attack [1]. Since there is currently no effective prevention against RI there is ongoing interest in the use of adjunctive cardioprotective agents and procedures to be applied before/during myocardial reperfusion to limit infarct size [4,5,6] Such protective measures may be valuable in the peri-operative setting for patients undergoing cardiopulmonary bypass for cardiac surgery. Endogenous nitric oxide (NO) may contribute to ischemic and anesthetic preconditioning while exogenous NO protects against ischemia-reperfusion (I/R) injury in the heart and other organs. Why those beneficial effects observed in animal models do not always translate into clinical effectiveness remains unclear.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.